Combination chemotherapy of solid tumors: An American-Italian collaboration: A celebration of the work of Gianni Bonadonna

Tumori

Volumn 102, Issue 2, 2016, Pages 124-126

  De Vita, Vincent T ^a   Canellos, George P ^b  

^a YALE CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ABVD; C MOPP; Diffuse large B cell lymphoma; Hodgkin's; Lymphoma; MOPP

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; AMSACRINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AMERICAN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; DRUG EFFICACY; EVENT FREE SURVIVAL; HEALTH CARE ORGANIZATION; HODGKIN DISEASE; HUMAN; ITALIAN (CITIZEN); LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROFESSIONAL PRACTICE; REVIEW; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); COOPERATION; DRUG ADMINISTRATION; FEMALE; HISTORY; ITALY; LIFE TABLE; LYMPHOMA, NON-HODGKIN; MALE; MORTALITY; NATIONAL HEALTH ORGANIZATION; ONCOLOGY; UNITED STATES;

AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HODGKIN DISEASE; HUMANS; ITALY; LIFE TABLES; LYMPHOMA, NON-HODGKIN; MALE; MECHLORETHAMINE; MEDICAL ONCOLOGY; METHOTREXATE; NATIONAL CANCER INSTITUTE (U.S.); PREDNISONE; PROCARBAZINE; UNITED STATES; VINCRISTINE;

EID: 84969141669     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000492     Document Type: Review

References (20)

1. Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC. Cyclical combination chemotherapy for advanced breast carcinoma. BMJ. 1974;1(5901):218-220.
2. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73(6):881-895.
3. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294(8):405-410.
4. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304(1):10-15.
5. Tancini G, Bonadonna G, Valegusa P, et al. Adjuvant CMF in breast cancer Comparative 5 year results of 12 vs 6 cycles. J. Clin. Onc. 1983;1:1,2-10.
6. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F. Clinical evaluation of adriamycin, a new antitumour antibiotic. BMJ. 1969;3(5669):503-506.
7. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev. 1982;9(1):21-35.
8. Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982;96(2):139-143.
9. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252-259.
10. Bonadonna G. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1982;42(11):4309-4320.
11. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
12. Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol. 1991;9(6):906-917.
13. Longo DL, Glatstein E, Duffey PL, et al. A prospective trial of radiation alone vs combination chemotherapy alone for early-stage Hodgkin's disease: implications of 25-year followup to current combined modality therapy. Pro Am Soc Hem. 2006;108(11), Abstract 98.
14. DeVita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet. 1975;1(7901):248-250.
15. Bonadonna G, De Lena M, Lattuada A, Milani F, Monfardini S, Beretta G. Combination chemotherapy and radiotherapy in non-Hodgkin's lymphomata. Br J Cancer Suppl. 1975;2:481-488. (Suppl II).
16. Bajetta E, Buzzoni R, Valagussa P, Bonadonna G. Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas. Am J Clin Oncol. 1988;11(2):100-103.
17. Bajetta E, Buzzoni R, Viviani S, et al. Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas. Cancer Treat Rep. 1985;69(9):965-969.
18. Gianni AM, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces4 hematologic toxicity and widens clinical applicability of highdose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol. 1990;8(5):768-778.
19. Tondini C, Zanini M, Lombardi F, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol. 1993;11(4): 720-725.
20. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336(18):1290-1297.